Author:
Thadani Udho,Chrysant Steven,Gorwit Jeffrey,Giles Thomas,Archer Stephen,Iteld Bruce,Singh Steven,Copen David,Wakeford Charles,Hobbs Stuart
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine
Reference27 articles.
1. Hof RP, Scholtysik G, Loutzenhiser R, Vuorela HJ, Neumann P. PN 200-110, a new calcium antagonist: electrophysiological, inotropic, and chronotropic effects on guinea pig myocardial tissue and effects on contraction and calcium uptake of rabbit aorta.J Cardiovasc Pharmacol 1984;6:399?406.
2. Wada Y, Satoh K, Taira N. A study on the separation of the coronary vasodilator from the cardiac effects of PN 200-100, a new dihydrophyridine calcium antagonist, in the dog heart.J Cardiovasc Pharmacol 1985;7:190?196.
3. van Wijk LM, van den Toren WE, van Gelder I, Crijns JH, Ruegg P, Lie KI. Electrophysiological properties of isradipine (PN 200-110) in humans.J Cardiovasc Pharmacol 1989;14:492?495.
4. van Wijk LM, van den Toren EW, van Gelder I, Crijns HJ, Lie KI. Electrophysiological properties of intravenously applied isradipine (PN 200-110) in man with normal sinus node and AV nodal function. Influence of beta-blockade. In: van Zwieten PA, ed.Calcium Antogonists. Royal Society of Medicine Services International Congress and Symposium Series no. 142, 1988:75?82.
5. Mauser M, Voeker W, Ickrath O, Karsh KR. Myocardial properties of the new dihydropyridine calcium antagonist isradipine compared to nifedipine with or without additional beta blockage in coronary artery disease.Am J Cardiol 1989;63:40?44.